Screener
Maze Therapeutics MAZE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | $20M— | —— | —— | $0-100% | ||
| $34.94M+24.3% | $34.15M+23.8% | $27.57M+24.1% | $25.19M+26.9% | $28.11M+43.8% | ||
| $13.1M+56.5% | $12.41M+58.6% | $10.49M+39.7% | $7.78M+13.1% | $8.37M+41.8% | ||
| $48.04M+31.7% | $46.55M+31.5% | $38.06M+28.0% | $32.97M+23.3% | $36.47M+43.3% | ||
| -$48.04M-31.7% | -$26.55M+25.0% | -$38.06M— | -$32.97M-36.1% | -$36.47M-126% | ||
| $931K— | $866K— | —— | —— | —— | ||
| $3.31M+18.4% | $2.35M-10.3% | —— | —— | $2.8M— | ||
| -$44.73M-32.8% | -$24.21M+26.2% | -$34.57M— | -$30.09M-21.6% | -$33.68M-124% | ||
| -$0.76+1.3% | -$0.45+60.9% | -$0.60-103% | -$0.66+93.6% | -$0.77-124% | ||
| -$47.64M-33.0% | -$26.11M+24.8% | -$37.56M— | -$32.39M-38.2% | -$35.83M-126% | ||
| -$48.04M-31.7% | -$26.55M+25.0% | -$38.06M— | -$32.97M-36.1% | -$36.47M-126% |
FAQ
- Is Maze Therapeutics profitable?
- Maze Therapeutics is not currently profitable: it reported a net loss of $133.6M over the trailing twelve months.
- What is Maze Therapeutics's earnings per share?
- Maze Therapeutics's diluted EPS over the trailing twelve months is $-2.47.
- Where does Maze Therapeutics's income statement data come from?
- Every line is extracted from Maze Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.